Test Price
2,800 AED✅ Home Collection Available
LHFPL5 Gene Deafness (Autosomal Recessive Type 67) NGS Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited NGS processing and bioinformatics pipeline.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic post‑test clinical interpretation and mandatory pre‑test genetic counselling session (pedigree chart).
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The LHFPL5 gene test detects pathogenic variants causing autosomal recessive deafness type 67 (DFNB67), delivering actionable genetic diagnosis for early intervention and family planning. Utilising high‑coverage Next Generation Sequencing, it achieves sub‑single‑base resolution and a clinical confidence exceeding 99.9%.
| Parameter | DNA Labs UAE – LHFPL5 NGS Test | Closest Alternative (Standard Hearing Loss Panel) |
|---|---|---|
| Precision | 99.9% sensitivity with targeted deep sequencing ±100× coverage, validated by Sanger confirmation | Varied; may miss rare deep‑intronic variants |
| Methodology | NGS (Illumina NovaSeq) – full LHFPL5 coding region ±20 bp splice sites | Multiplex PCR or exome‑based panels |
| Turnaround Time | 3–4 weeks with prioritised reporting | 4–6 weeks |
| Price | 2800 AED | Varies; often higher for focused gene analysis |
| Genetic Counseling | Mandatory pre‑test pedigree session included | Not always provided |
Physician Insight & Safety Protocols
“The LHFPL5 gene test provides a definitive molecular diagnosis for families affected by hereditary hearing loss. This information is critical for guiding auditory rehabilitation and informed reproductive decisions. I always emphasize the importance of interpreting genetic results in conjunction with an audiologist and a clinical geneticist.”
— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Pre-Test Advisory
All genetic testing requires mandatory pre‑test counseling to construct a pedigree chart and discuss implications for family members. Patients should bring complete family medical history records. A signed informed consent form is required in compliance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Exclusion Criteria & ER Red Flags
- Exclusion: Sample contamination, insufficient DNA (<1 µg), lack of clinical history or signed consent.
- ER Red Flags: Sudden unilateral or bilateral hearing loss, acute vertigo, or focal neurological deficits require immediate ENT/neurology evaluation, not a genetic test.
- Minors: Valid parental consent and post‑test genetic counselling are mandatory per Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Patient FAQ & Clinical Guidance
1. How does the LHFPL5 gene mutation lead to hearing loss?
LHFPL5 gene mutations impair inner ear hair cell stereocilia, causing autosomal recessive non‑syndromic hearing loss DFNB67. The encoded protein, tetraspan membrane protein of hair cell stereocilia, is essential for mechanoelectrical transduction; biallelic loss‑of‑function variants result in congenital, severe‑to‑profound bilateral sensorineural deafness that is stable over time.
2. Who should consider this genetic test?
Individuals with congenital bilateral sensorineural hearing loss and a family history of deafness should consider this test. It is especially indicated when auditory neuropathy or syndromic features have been excluded and an autosomal recessive inheritance pattern is suspected.
3. How is the sample collected, and what is the turnaround time?
A blood sample, extracted DNA, or a single drop on an FTA card is collected at your home via our VIP Mobile Phlebotomy service (available daily 8 AM–11 PM). The specimen is processed using NGS with rigorous quality metrics (Q30 ≥ 85%), and results are reported within 3–4 weeks.
UAE Regulatory & Data Privacy Adherence
All clinical and genetic data are handled in strict compliance with:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL)
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree‑Law No. 4 of 2016 on Medical Liability
DNA Labs UAE operates under DHA Facility License No. 1143. The laboratory is ISO 9001:2015 certified (Certificate: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | LHFPL5 Gene Deafness (Autosomal Recessive Type 67) NGS Test |
| Price (AED) | 2800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card (collected via VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection) |
| Methodology Used | Next Generation Sequencing (Illumina NovaSeq) – full LHFPL5 coding region ±20 bp splice sites |
| ICD-10-CM Code | H90.3 (Bilateral sensorineural hearing loss) |
| LOINC Code | 93597-4 (LHFPL5 gene targeted mutation analysis) |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians